EP1622605B1 - Utilisation de derives phtalides pour assurer le traitement et la prophylaxie du diabete sucre - Google Patents

Utilisation de derives phtalides pour assurer le traitement et la prophylaxie du diabete sucre Download PDF

Info

Publication number
EP1622605B1
EP1622605B1 EP04731138A EP04731138A EP1622605B1 EP 1622605 B1 EP1622605 B1 EP 1622605B1 EP 04731138 A EP04731138 A EP 04731138A EP 04731138 A EP04731138 A EP 04731138A EP 1622605 B1 EP1622605 B1 EP 1622605B1
Authority
EP
European Patent Office
Prior art keywords
senkyunolide
diabetes mellitus
treatment
formula
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP04731138A
Other languages
German (de)
English (en)
Other versions
EP1622605A1 (fr
Inventor
Ying Wang
Antoine De Saizieu
Göde SCHÜLER
Daniel D'orazio
Daniel RÄDERSTORFF
Swen Wolfram
Peter Weber
Sandra Teixeira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Priority to EP04731138A priority Critical patent/EP1622605B1/fr
Publication of EP1622605A1 publication Critical patent/EP1622605A1/fr
Application granted granted Critical
Publication of EP1622605B1 publication Critical patent/EP1622605B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to the use of a compound as effective agent for the prevention or treatment of diabetes mellitus in a mammal.
  • Said compounds being selected from the group of phthalide derivatives and are useful for the preparation of a pharmaceutical or a dietary composition given to a mammal in need thereof for the prevention or treatment of diabetes mellitus.
  • Diabetes mellitus defines a complex of metabolic diseases derived from multiple causative factors and is characterized by impaired carbohydrate, protein and fat metabolism associated with a deficiency in insulin secretion and/or insulin resistance. This results in elevated fasting and postprandial serum glucose that leads to complications if left untreated.
  • type 1 diabetes mellitus (2) type 2 diabetes mellitus, (3) the so-called gestational diabetes mellitus, which begins or is recognized for the first time during pregnancy, and (4) some other forms which are mainly based on genetic defects.
  • Type 1 and type 2 diabetes mellitus are associated with hyperglycemia, hypercholesterolemia and hyperlipidemia.
  • the insensitivity to insulin and absolute insulin deficiency in type 1 and 2 diabetes mellitus leads to a decrease in glucose utilization by the liver, muscle and the adipose tissue and to an increase in the blood glucose levels.
  • Uncontrolled hyperglycemia is associated with increased and premature mortality due to an increased risk for microvascular and macrovascular diseases, including nephropathy, neuropathy, retinopathy, hypertension, stroke, and heart disease.
  • Type 1 diabetes mellitus is the form of diabetes mellitus which usually begins with childhood or puberty and is characterized by an auto-immune destruction of the insulin-producing ⁇ -cells leading to a complete deficiency of insulin secretion.
  • Type 2 diabetes mellitus is the form of diabetes mellitus which occurs predominantly in adults in whom adequate production of insulin is available for use, yet a defect exists in insulin-mediated utilization and metabolism of glucose in peripheral tissues. The changes in various tissues associated with type 2 diabetes mellitus exist even before clinical symptoms are detected.
  • Type 2 diabetes mellitus initially involves dietary and lifestyle changes, when these measures fail to maintain adequate glycemic control the patients are treated with oral hypoglycemic agents and/or exogenous insulin.
  • the current oral pharmacological agents for the treatment of type 2 diabetes mellitus include those that potentiate insulin secretion (sulphonylurea agents), those that improve the action of insulin in the liver (biguanide agents), insulin sensitizing agents (thiazolidinediones) and agents which act to inhibit the uptake of glucose in the gastrointestinal tract ( ⁇ -glucosidase inhibitors).
  • PPARs peroxisome proliferator-activated receptors
  • the PPARs are activated to various degrees by high concentrations of long-chain fatty acids.
  • Synthetic PPAR ligands including the fibrates and thiazolidinediones, have proven effective in the treatment of dyslipidemia and diabetes mellitus , especially type 2 diabetes mellitus.
  • these compounds act with PPAR ⁇ , which is one isoform of the PPAR family, some of them are also able to interact with PPAR ⁇ and/or PPAR ⁇ isoform.
  • Type 2 diabetes mellitus is a progressive and chronic disease, which usually is not recognized until significant damage has occurred to the pancreatic cells responsible for producing insulin and to the cardiovascular system. Therefore, there is also an increasing interest in the development of a dietary supplement that may be used to prevent the development of diabetes mellitus in people at risk especially in elderly who are at high risk for developing diabetes mellitus.
  • a group of known compounds exhibit excellent blood glucose lowering effects and thus are effective agents in the prevention or treatment of diabetes mellitus in mammals.
  • These non-toxic compounds function as ligands for PPAR ⁇ .
  • Therapeutic effects of these ligands include, but are not limited to, a decrease in the blood glucose level, prevention of obesity, a lowered insulin resistance, delay or prevention of type 2 diabetes mellitus and dyslipidemia, differentiation of adipocytes, lowered triglyceride levels, and normalized glucose tolerance.
  • the object of the present invention is the use of a compound represented by formula (I) as antidiabetic agent, wherein the dotted line is an optional bond;
  • X is X2, X3, or X5 in case of a tetrahydrofuran, i.e., if the dotted line in formula (I) does not signify a bond whereas X is X1, X4, or X5 in case of a dihydrofuran, i.e., if the dotted line in formula (I) signifies a bond.
  • the term "antidiabetic agent” means an agent which is capable of preventing or treating diabetes mellitus, especially type 2 diabetes mellitus, in a mammal which is in need thereof. These agents are also useful for the treatment or prevention of related symptoms.
  • diabetes mellitus also includes, but is not limited to, related symptoms such as increased blood glucose level, obesity, increased insulin resistance, hyperlipidemia, dyslipidemia, increase in cholesterol (hypercholesterinemia, hypertriglycerinemia), hyperinsulinemia, and impaired glucose tolerance. Impaired glucose tolerance and impaired fasting glucose are the two symptoms referred to as pre- diabetes mellitus . This stage is associated with the so-called insulin resistance syndrome also known as syndrome X. Since syndrome X is directly involved in the pathogenesis of type 2 diabetes mellitus , the compounds used for the present invention are also useful for the treatment or prevention of syndrome X.
  • An agonist of PPAR ⁇ relates to a small molecule interacting directly with PPAR ⁇ , particularly with its ligand binding domain, and thus activating the PPAR ⁇ .
  • the compounds as used for the present invention are selected from the group of phthalide derivatives, which refer to substituted lactones of 2-hydroxymethylbenzoic acid according to IUPAC Rule C-473. This class of compounds is based on 1(3H)-isobenzofuranone C 8 H 6 O 2 .
  • Preferred compounds used as antidiabetic agents are selected from the group consisting of (E)-senkyunolide E; senkyunolide C; senkyunolide B; 3-butyl-4,5,6,7-tetrahydro-3,6,7-trihydroxy-1(3H)-isobenzofuranone; 3-butyl-1(3H)-isobenzofuranone; 3-butylphthalide; 3-butylidenephthalide; chuangxinol; ligustilidiol; senkyunolide F; 3-hydroxy-senkyunolide A; angeloylsenkyunolide F; senkyunolide M; 3-hydroxy-8-oxo-senkyunolide A; ligustilide; 6,7-dihydro-(6S,7R)-dihydroxyligustilide; 3a,4-dihydro-3-(3-methylbutylidene)-1(3H)-isobenzofuran
  • the most preferably used compounds are selected from the group consisting of ligustilide, 3-butylphthalide, 3-butylidenephthalide, and sedanolide.
  • the preferred embodiments are listed in Table 1.
  • Table 1 List of preferred compounds used as antidiabetic agents Structure Name (E)-Senkyunolide E Senkyunolide C Senkyunolide B 3-Butyl-4,5,6,7-tetrahyclro-3,6,7-trihydroxy-1(3H)-isobenzofuranone 3-Butyl-1(3H)-isobenzofuranone 3-Butylphthalide 3-Butylidenephthalide Chuangxinol Ligustilidiol Senkyunolide F 3-Hydroxy-senkyunolide A Angeloylsenkyunolide F Senkyunolide M 3-Hydroxy-8-oxo-senkyunolide A Ligustilide 6,7-Dihydro-(6S,7R)-dihydroxylig
  • a compound which is selected from the group consisting ofligustilide, 3-butylphthalide, 3-butylidenephthalide, and sedanolide as antidiabetic agent.
  • the compounds according to formula (I) as defined above are used for the preparation of a pharmaceutical or dietary composition for the prevention or treatment of diabetes mellitus.
  • Preferred compounds are represented in Table 1.
  • the most preferably used compounds are selected from the group consisting of ligustilide, 3-butylphthalide, 3-butylidenephthalide, and sedanolide.
  • Another aspect of the present invention is the provision of a pharmaceutical or dietary composition for use in the treatment or prevention of diabetes mellitus comprising an effective amount of a compound of formula (I) as defined above.
  • Preferred compounds are represented in Table 1. The most preferred compounds are selected from the group consisting ofligustilide, 3-butylphthalide, 3-butylidenephthalide, and sedanolide.
  • a pharmaceutical composition may further comprise pharmaceutically acceptable carriers, excipients or diluents, including, but not limited to, lubricants, colorants, wetting agents, fillers, disintegrants and flavorants.
  • a dietary composition may further comprise any known substances which are normally used and accepted in the preparation of such compositions.
  • the pharmaceutical or dietary composition may be in the form which is selected from the group consisting of fortified food or feed, beverages, tablets, granules, capsules, pastes, and effervescent formulations.
  • the pastes may be filled into hard or soft gelatin capsules.
  • the present invention provides a method for the prevention or treatment of diabetes mellitus and in mammals, said method comprising:
  • an "effective dose" of the compounds of the present invention is an amount which is high enough to effect activation of PPAR ⁇ and thus lowering the blood glucose level in a mammal.
  • a suitable dose is within the range of about 0.01 to about 50 mg/kg body weight/day.
  • the compounds according to formula (I) as defined above and which are used as antidiabetic agents may be isolated by methods known in the art [see, e.g., Beck J.J. and Stermitz F.R., J. Natural Products, Vol. 58, No. 7, pp.
  • the ligustilide as used herein was purchased from GAIA Chemical Corporation, 23 George Washington Plaza, Gaylorsville, CT 06755, USA and has a purity of about 95% (purified by column chromatography).
  • C3H10T1/2 cells (ATCC CCL-226) were grown for 5 days to confluence in DMEM supplemented with 10% FBS medium and induced with a mixture of insulin, dexamethasone and 3-isobutyl-1-methylxanthine to differentiate into adipocytes.
  • ligustilide Nine days after the beginning of induction, cells were treated for 48-h with ligustilide at different concentrations as shown in Table 2.
  • Glucose uptake was determined using radioactive 2-deoxyglucose (10 ⁇ M 2-DG in HBS + 0.5 ⁇ Ci/ml of 3[H]-2-DG), measuring glucose uptake in the absence of insulin. Basal glucose uptake was increased by 48-h treatment with ligustilide in a dose-dependent manner (Table 2).
  • 3-butylphthalide as used herein was purchased from Advanced Synthesis Technologies, P.O. Box 437920, San Ysidro, CA 92173, USA.
  • 3-butylidenephthalide as used herein was purchased from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA and has a purity of >96%.
  • C3H10T1/2 cells were grown to confluence as described in Example 1, then treated for 10 days with insulin alone (negative control) or with a mixture of insulin and ligustilide at different concentrations (see Table 3), with re-feeding with fresh medium and compounds every 48-h. After the 10-day treatment, the cells were stained with oil Red O as follows: cells were washed 2x in PBS and fixed in 10% formalin at room temperature for 1 h. After removal of formalin, 200 ⁇ l of oil Red O staining solution (3:2 mixture of 0.5% w/v oil Red O stock solution and water) was applied to each well.
  • the cells were incubated for 20 min at room temperature, washed twice in 2x PBS and incubated for 10 min with 300 ⁇ l of isopropanol/well for oil Red O extraction. Quantification of oil Red O was determined by measuring absorbance at 540 nm (mean OD). Co-treatment of C3H10T1/2 cells with insulin and ligustilide resulted in a higher differentiation of the cells into adipocytes than insulin alone as represented by a higher amount of oil Red O staining (Table 3).
  • C3H10T1/2 cells were grown and treated as described in Example 4 with the exception that 3-butylphthalide was used instead of ligustilide.
  • the measurement of adipocyte differentiation using the oil Red O assay was performed as described in Example 4.
  • Co-treatment of C3H10T1/2 cells with insulin and 3-butylphthalide resulted in a higher differentiation of the cells into adipocytes than insulin alone (Table 4).
  • C3H10T1/2 cells were grown and treated as described in Example 4 with the exception that 3-butylidenephthalide was used instead of ligustilide.
  • the measurement of adipocyte differentiation using the oil Red O assay was performed as described in Example 4.
  • Co-treatment of C3H10T1/2 cells with insulin and 3-butylidenephthalide resulted in a higher differentiation of the cells into adipocytes than insulin alone (Table 4).
  • the 3-butylphthalide as used herein was purchased from Sigma, P.O. Box 14508, St. Louis, MO 63178, USA and has a purity of about >98%.
  • C3H10T1/2 cells were grown and treated as described in Example 4 with the exception that sedanolide was used instead of ligustilide.
  • the measurement of adipocyte differentiation using the oil Red O assay was performed as described in Example 4.
  • Co-treatment of C3H10T1/2 cells with insulin and sedanolide resulted in a higher differentiation of the cells into adipocytes than insulin alone (Table 5).
  • mice Male db / db mice were obtained from Jackson Laboratory (Bar Harbor, ME, USA). Adult mice aged 12 weeks were used in the experiment. Mice were housed individually in plastic cages with bedding and allowed free access to standard rodent food and tap water. The animal rooms were controlled for temperature (24°C), humidity (55%), and light (12-h light-dark cycle). The animals were randomized in two groups and ligustilide was administered orally to one of the groups for 7 days at a dose of 200 mg/kg BW/day. After 7 days of treatment the concentration of glucose was determined in blood from fed animals, i.e., animals which were not restricted from food. After a period of 5 days of treatment an oral glucose tolerance test (OGTT) was performed.
  • OGTT oral glucose tolerance test
  • OGTT mice were fasted overnight and then a 1-g glucose/kg BW solution was orally administered. Blood samples were taken before and 15, 30, 45, 60, 90, 120, 150, 180 min after the glucose challenge for determination of blood glucose levels and then the area under the curve (AUC) was determined. Blood glucose was measured by a glucose analyzer (Glucotrend Premium, Roche Diagnostics, Rotnch, Switzerland). The blood glucose levels and AUC for the OGTT measurement are given in Table 6. The glucose levels of fed animals (see above) were significantly lowered after 7 days of ligustilide treatment.
  • ligustilide significantly reduced the glucose AUC of an OGTT (1 g glucose/kg body weight) on day 5.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Fodder In General (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicines Containing Plant Substances (AREA)

Claims (6)

  1. Utilisation d'un composé représenté par la formule (I) pour la préparation d'une composition pharmaceutique ou alimentaire destinée à la prévention ou au traitement du diabète sucré,
    Figure imgb0030
     dans laquelle
    la ligne en pointillé est une liaison éventuelle ; R1 est butyle ou butyryle si R2 est hydroxy mais est butyle si R2 est hydrogène ; ou R1 et R2 pris ensemble sont 1-butylidène éventuellement substitué par hydroxy, méthyle ou
    3-(α,β-diméthylacrylyloxy)-pentylidényle ;
    X est un résidu choisi dans le groupe constitué de X1, X2, X3, X4 et X5 ;
    Figure imgb0031
    dans lesquels
    X est X2, X3 ou X5 si la ligne en pointillé ne signifie pas une liaison dans la formule (I) ci-dessus et X est X1, X4 ou X5 si la ligne en pointillé signifie une liaison dans la formule (I) ci-dessus ;
    R3 est hydroxy ou butyryle ; et
    n est 1 ou 2.
  2. Utilisation d'une composition selon la revendication 1, caractérisée en ce que la composition est une composition alimentaire sous forme d'aliment pour l'homme ou les animaux ou de boisson enrichi(e), de comprimés, de granulés, de capsules, de pâtes ou de formulations effervescentes.
  3. Utilisation d'un composé selon la revendication 2, caractérisée en ce que le composé est choisi dans le groupe constitué de : (E)-senkyunolide E ; senkyunolide C ; senkyunolide B ; 3-butyl-4,5,6,7-tétrahydro-3,6,7-trihydroxy-1(3H)-isobenzofuranone ; 3-butyl-1(3H)-isobenzofuranone ; 3-butylphtalide ; 3-butylidène-phtalide ; chuangxinol ; ligustilidiol ; senkyunolide F ; 3-hydroxy-senkyunolide A ; angeloylsenkyunolide F ; senkyunolide M ; 3-hydroxy-8-oxo-senkyunolide A ; ligustilide ; 6,7-dihydro-(6S,7R)-dihydroxyligustilide ; 3a,4-dihydro-3-(3-méthylbutylidène)-1(3H)-isobenzofuranone ; sédanolide ; et onidilide.
  4. Utilisation d'une composition selon l'une quelconque des revendications 1 à 3, caractérisée en ce que le composé est choisi dans le groupe constitué de ligustilide, 3-butylphtalide, 3-butylidène-phtalide et sédanolide.
  5. Utilisation d'une composition selon la revendication 1, caractérisée en ce que la composition pharmaceutique comprend en outre un support, des excipients ou des diluants pharmaceutiquement acceptables.
  6. Utilisation d'un composé représenté par la formule (I) pour la préparation d'une composition pharmaceutique ou alimentaire destinée à la prévention ou au traitement du syndrome X,
    Figure imgb0032
     dans laquelle
    la ligne en pointillé est une liaison éventuelle ; R1 est butyle ou butyryle si R2 est hydroxy mais est butyle si R2 est hydrogène ; ou R1 et R2 pris ensemble sont 1-butylidène éventuellement substitué par hydroxy, méthyle ou
    3-(α,β-diméthylacrylyloxy)-pentylidényle ;
    X est un résidu choisi dans le groupe constitué de X1, X2, X3, X4 et X5 ;
    Figure imgb0033
    dans lesquels
    X est X2, X3 ou X5 si la ligne en pointillé ne signifie pas une liaison dans la formule (I) ci-dessus et X est X1, X4 ou X5 si la ligne en pointillé signifie une liaison dans la formule (I) ci-dessus ;
    R3 est hydroxy ou butyryle ; et
    n est 1 ou 2.
EP04731138A 2003-05-14 2004-05-05 Utilisation de derives phtalides pour assurer le traitement et la prophylaxie du diabete sucre Expired - Lifetime EP1622605B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04731138A EP1622605B1 (fr) 2003-05-14 2004-05-05 Utilisation de derives phtalides pour assurer le traitement et la prophylaxie du diabete sucre

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03010804 2003-05-14
PCT/EP2004/004768 WO2004100945A1 (fr) 2003-05-14 2004-05-05 Utilisation de derives phtalides pour assurer le traitement et la prophylaxie du diabete sucre
EP04731138A EP1622605B1 (fr) 2003-05-14 2004-05-05 Utilisation de derives phtalides pour assurer le traitement et la prophylaxie du diabete sucre

Publications (2)

Publication Number Publication Date
EP1622605A1 EP1622605A1 (fr) 2006-02-08
EP1622605B1 true EP1622605B1 (fr) 2009-07-15

Family

ID=33442726

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04731138A Expired - Lifetime EP1622605B1 (fr) 2003-05-14 2004-05-05 Utilisation de derives phtalides pour assurer le traitement et la prophylaxie du diabete sucre

Country Status (8)

Country Link
US (2) US20070082947A1 (fr)
EP (1) EP1622605B1 (fr)
JP (2) JP4804353B2 (fr)
KR (1) KR101207652B1 (fr)
CN (1) CN100562314C (fr)
DE (1) DE602004022035D1 (fr)
ES (1) ES2327639T3 (fr)
WO (1) WO2004100945A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1605336A (zh) 2003-10-10 2005-04-13 中国医学科学院药物研究所 左旋丁基苯酞在制备预防和治疗脑梗塞的药物中的应用
KR20080015802A (ko) * 2005-05-24 2008-02-20 디에스엠 아이피 어셋츠 비.브이. 염증 질환의 치료를 위한 리구스틸라이드 유도체
CN101563080A (zh) * 2006-08-11 2009-10-21 帝斯曼知识产权资产管理有限公司 用于治疗中枢神经病症的藁本内酯衍生物
JP2009256208A (ja) * 2006-08-17 2009-11-05 Dainippon Sumitomo Pharma Co Ltd フタリド誘導体またはその薬学的に許容される塩
CN101302208B (zh) * 2008-03-04 2012-12-26 中央民族大学 抑制谷胱甘肽s-转移酶活性的化合物、其制备方法、其应用
AU2011213921A1 (en) * 2010-02-10 2012-08-09 Mapi Pharma Limited Preparation of benzofurans and use thereof as synthetic intermediates
JP5581120B2 (ja) * 2010-06-07 2014-08-27 花王株式会社 電位依存性カチオンチャネル抑制剤
CN102267977B (zh) * 2011-05-06 2014-09-10 中国药科大学 一种3-取代苯并[c]呋喃酮的硫代、硒代同系物、其制备方法及医药用途
TWI484033B (zh) * 2013-01-25 2015-05-11 Univ China Medical 培養幹細胞之方法及套組
CN104546827B (zh) * 2013-10-09 2019-12-27 石药集团恩必普药业有限公司 丁基苯酞或其衍生物在制备治疗或预防糖尿病的药物中的应用
CN104546828B (zh) * 2013-10-09 2017-11-14 石药集团恩必普药业有限公司 丁基苯酞或其衍生物在制备治疗或预防糖尿病并发症的药物中的应用
TWI547280B (zh) * 2014-04-24 2016-09-01 長弘生物科技股份有限公司 穩定醫藥組合物
TWI625391B (zh) * 2014-09-17 2018-06-01 國璽幹細胞應用技術股份有限公司 藁本內酯之應用
WO2017102790A1 (fr) * 2015-12-18 2017-06-22 Dsm Ip Assets B.V. Analogues de la vitamine d constitués de composés biaromatiques
WO2017198071A1 (fr) * 2016-05-20 2017-11-23 国立东华大学 Applications du butylidènephtalide
ES2933150B2 (es) * 2021-07-29 2023-08-03 Univ Cadiz Uso de 3-arilftalidas y sus derivados como agentes antiinflamatorios

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
JPH01207233A (ja) * 1988-02-12 1989-08-21 Tsumura & Co 抗動脈硬化症剤
JPH01254671A (ja) * 1988-04-05 1989-10-11 Tsumura & Co 新規リグスチリド類
JPH05247022A (ja) * 1990-07-10 1993-09-24 Tsumura & Co 新規フタリドおよびフタリドを有効成分とする脳機能改善剤
JPH04173740A (ja) * 1990-11-06 1992-06-22 Kobe Steel Ltd フタライド類含有植物・生薬エキス抽出法
NZ267567A (en) * 1993-06-25 1997-10-24 Main Camp Marketing Pty Ltd Su Treatment of inflammatory conditions using various indole, benzoquinone and benzofuran derivatives; method of plant material extraction; celery seed extract
CN1069036C (zh) 1995-07-21 2001-08-01 崔景岳 灵芝仙饮
JP4719372B2 (ja) * 2000-06-21 2011-07-06 花王株式会社 Ｐｐａｒ依存的遺伝子転写活性化剤
CN1182127C (zh) * 2000-06-28 2004-12-29 中国医学科学院药物研究所 新的取代的2-苯并[c]呋喃酮化合物,其制备方法以及包含它们的药物组合物
ITRM20010136A1 (it) * 2001-03-16 2002-09-16 Sigma Tau Ind Farmaceuti Composti utili per il trattamento di patologie che rispondono all'attivazione del recettore ppar-gamma.
DE10131057A1 (de) * 2001-06-29 2003-01-23 Shandong Luya Pharmaceutical C Weiche, Angelikaöl enthaltende Gelkapsel und deren Herstellung
JP2003171303A (ja) * 2001-09-17 2003-06-20 Suzuka Univ Of Medical Science 特定植物含有組成物と該組成物を有効成分とする医薬品と保健用食品
US20030165580A1 (en) * 2002-03-04 2003-09-04 Xinxian Zhao Safe pharmaceutical composition for treatment and prevention of gynecological disease
KR100504408B1 (ko) * 2002-10-29 2005-07-27 주식회사 코리아나화장품 생큐노라이드 ａ를 포함하는 피부 미백용 화장료 조성물

Also Published As

Publication number Publication date
DE602004022035D1 (de) 2009-08-27
WO2004100945A1 (fr) 2004-11-25
US20070082947A1 (en) 2007-04-12
CN100562314C (zh) 2009-11-25
KR20060011865A (ko) 2006-02-03
US20090192218A1 (en) 2009-07-30
JP2006528666A (ja) 2006-12-21
EP1622605A1 (fr) 2006-02-08
KR101207652B1 (ko) 2012-12-03
JP2012006923A (ja) 2012-01-12
JP5249388B2 (ja) 2013-07-31
JP4804353B2 (ja) 2011-11-02
CN1787815A (zh) 2006-06-14
US8242168B2 (en) 2012-08-14
ES2327639T3 (es) 2009-11-02

Similar Documents

Publication Publication Date Title
US8242168B2 (en) Use of phthalide derivatives for the treatment of type 2 diabetes mellitus
EP1811991B1 (fr) Traitement du diabete de type 2 en utilisant d'inhibiteurs de la synthese des glycosphingolipides
KR100877600B1 (ko) 메타독신 및 마늘유를 유효성분으로 함유하는 알코올성지방간 및 지방간성 간염의 예방 및 치료용 약학 조성물
KR101934328B1 (ko) 아모디아퀸 및 항당뇨 약물을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물
US11938122B2 (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3- thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
EP2675275A1 (fr) Compositions et méthodes utilisables en vue du traitement de l'obésité et des troubles associés
KR20140008452A (ko) 진성 당뇨병을 치료하기 위한 병용제
KR101668443B1 (ko) 아모디아퀸을 유효성분으로 함유하는 대사성 질환의 예방, 개선, 또는 치료용 조성물
Ha et al. Beneficial Effects of a Curcumin Derivative and Transforming Growth Factor-β Receptor I Inhibitor Combination on Nonalcoholic Steatohepatitis
KR20080019243A (ko) 비자가면역 제 2 형 진성당뇨병 및/또는 신드롬 ｘ의치료용 화합물
EP3804705B1 (fr) Composition pharmaceutique destinée à prévenir le diabète et utilisation correspondante
CN109498623A (zh) 改善肝功能的方法
JP4914714B2 (ja) 脂質代謝異常の予防または治療用医薬組成物
JP2014526521A (ja) 代謝疾患、心臓血管疾患および炎症の処置のためのプテロスチルベンとスタチンとの組み合わせ
KR101476738B1 (ko) 인슐린 저항성 개선제
KR100697097B1 (ko) 당뇨병 예방 또는 치료용 약학 조성물
JP6280050B2 (ja) 肥満症予防又は治療剤，リウマチの予防又は治療剤
Gras Resmetirom. Thyroid hormone receptor-beta agonist, Treatment of nonalcoholic steatohepatitis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: D'ORAZIO, DANIEL

Inventor name: WANG, YING

Inventor name: WOLFRAM, SWEN

Inventor name: SCHUELER, GOEDE

Inventor name: DE SAIZIEU, ANTOINE

Inventor name: TEIXEIRA, SANDRA

Inventor name: WEBER, PETER

Inventor name: RAEDERSTORFF, DANIEL

RIN1 Information on inventor provided before grant (corrected)

Inventor name: D'ORAZIO, DANIEL

Inventor name: WOLFRAM, SWEN

Inventor name: WANG, YING

Inventor name: SCHUELER, GOEDE

Inventor name: WEBER, PETER

Inventor name: DE SAIZIEU, ANTOINE

Inventor name: TEIXEIRA, SANDRA

Inventor name: RAEDERSTORFF, DANIEL

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602004022035

Country of ref document: DE

Date of ref document: 20090827

Kind code of ref document: P

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2327639

Country of ref document: ES

Kind code of ref document: T3

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091015

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

26N No opposition filed

Effective date: 20100416

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100505

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20110525

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100505

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090715

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120531

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120531

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20200414

Year of fee payment: 17

Ref country code: DE

Payment date: 20200422

Year of fee payment: 17

Ref country code: ES

Payment date: 20200601

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20200422

Year of fee payment: 17

Ref country code: IT

Payment date: 20200414

Year of fee payment: 17

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602004022035

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20210505

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210505

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210531

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220705

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200505